CN106727641A - It is a kind of to treat medicine of bronchitis and preparation method thereof - Google Patents

It is a kind of to treat medicine of bronchitis and preparation method thereof Download PDF

Info

Publication number
CN106727641A
CN106727641A CN201611115454.9A CN201611115454A CN106727641A CN 106727641 A CN106727641 A CN 106727641A CN 201611115454 A CN201611115454 A CN 201611115454A CN 106727641 A CN106727641 A CN 106727641A
Authority
CN
China
Prior art keywords
parts
powder
acid
budesonide
bronchitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611115454.9A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou Renhong Pharmaceutical Technology Co Ltd
Original Assignee
Zhengzhou Renhong Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Renhong Pharmaceutical Technology Co Ltd filed Critical Zhengzhou Renhong Pharmaceutical Technology Co Ltd
Priority to CN201611115454.9A priority Critical patent/CN106727641A/en
Publication of CN106727641A publication Critical patent/CN106727641A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of medicine for treating bronchitis, it is made up of according to weight portion following raw material：18 32 parts of 48 parts of auxiliary material, 0.5 4 parts of tartaric acid, 38 parts of general flavone, 14 parts of mannitol, 5 10 parts of chlorpheniramine, 4 12 parts of metronidazole, 0.5 3 parts of aminophylline, 0.1 1.5 parts of anthocyanidin, 8 15 parts of morroniside, 0.1 0.5 parts of chlorphenamine maleate, 0.5 2 parts of oryzanol, 26 parts of budesonide, 26 parts of amino acid and ethanol solution.The present invention also disclosed the preparation method of the medicine.Raw material sources of the present invention are extensive, preparation process is simple, investment of production equipment low cost, it is adaptable to large-scale industrial production；The component such as chlorpheniramine, chlorphenamine maleate, budesonide plays synergy in the present invention, can fundamentally cure chronic bronchitis, and therapeutic effect is far superior to existing product and no toxic and side effect, wide market.

Description

It is a kind of to treat medicine of bronchitis and preparation method thereof
Technical field
The present invention relates to field of medicine preparation, specifically a kind of medicine for treating bronchitis.
Background technology
With the increase of life stress and increasing for various bad life habits, people face the threat of various diseases, branch Tracheitis is exactly one of which.Bronchitis refers to the chronic nonspecific inflammation of trachea-bronchial epithelial cell mucous membrane and its surrounding tissue. Bronchitis main cause is that the repeated infection of virus and bacterium forms bronchial chronic nonspecific inflammation.When under temperature Drop, the decline of respiratory tract small blood vessel spasm ischemic, defense function etc. are beneficial to pathogenic；The chronic stimulations such as smog dust, pollution air Can fall ill；Smoking makes bronchial spasm, mucous membrane variation, ciliary movement reduction, mucilage secretion increase advantageous infectivity；Intolerance factors There is certain relation.Bronchitis is divided into acute bronchitis and chronic bronchitis, and chronic bronchitis is most common of which, The patient for suffering with chronic bronchitis is to use drug therapy, but anti-inflammatory can only be alleviated or temporarily be played to existing medicine The effect of cough-relieving, it is impossible to fundamentally cure chronic bronchitis, this is just for patient brings inconvenience.
The content of the invention
It is an object of the invention to provide a kind of medicine for treating bronchitis, to solve what is proposed in above-mentioned background technology Problem.
To achieve the above object, the present invention provides following technical scheme：
A kind of medicine for treating bronchitis, is made up of following raw material according to weight portion：Auxiliary material 4-8 parts, tartaric acid 0.5-4 parts, it is total Flavones 3-8 parts, mannitol 1-4 parts, chlorpheniramine 5-10 parts, metronidazole 4-12 parts, aminophylline 0.5-3 parts, anthocyanidin 0.1-1.5 Part, morroniside 8-15 parts, chlorphenamine maleate 0.1-0.5 parts, oryzanol 0.5-2 parts, budesonide 2-6 parts, amino acid 2-6 Part and ethanol solution 18-32 parts.
As further scheme of the invention：General flavone uses flavonols, biflavone, isoflavones, flavanols and chalcone One or more mixture, tartaric acid using malic acid, citric acid, sugarcane acid and tussol one or more mixed Compound, amino acid uses one or more mixture of glutamic acid, lysine, aspartic acid and serine.
As further scheme of the invention：Auxiliary material uses dextrin, lactose, starch, methylcellulose, carboxymethylcellulose calcium With the mixture of one or more of stevioside, the weight fraction of ethanol solution is 45-65%.
The preparation method of the medicine of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, chlorphenamine maleate and budesonide are crushed and 100-120 mesh is crossed Sieve, obtains metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder and budesonide powder, standby With；
Step 2, by tartaric acid, general flavone, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder Added in ethanol solution with budesonide powder and mixer stirred 15-30 minutes with the rotating speed of 60-120rpm at normal temperatures, Obtain the first mixed solution；
Step 3, by mannitol, chlorpheniramine, anthocyanidin and oryzanol add the first mixed solution in and stir, while stirring Amino acid is added, is added completely into after amino acid finishes, mixer is stirred under 35-48 degrees Celsius with the rotating speed of 150-360rpm 45-90 minutes, then relative density is 1.20-1.30 when carrying out being concentrated under reduced pressure into 65 DEG C, obtains concentrate, then to carry out spraying dry Dry to obtain dry extract, addition auxiliary material is made pulvis, capsule, tablet or granule.
Compared with prior art, the beneficial effects of the invention are as follows：Extensively, preparation process is simple is raw for raw material sources of the present invention Produce equipment investment cost low, it is adaptable to large-scale industrial production；Chlorpheniramine, chlorphenamine maleate, cloth ground in the present invention The components such as Nai De play synergy, can fundamentally cure chronic bronchitis, therapeutic effect be far superior to existing product simultaneously And without toxic and side effect, wide market.
Specific embodiment
The technical scheme of this patent is described in more detail with reference to specific embodiment.
Embodiment 1
A kind of medicine for treating bronchitis, is made up of following raw material according to weight portion：4 parts of auxiliary material, 0.5 part of tartaric acid, general flavone 3 Part, 1 part of mannitol, 5 parts of chlorpheniramine, 4 parts of metronidazole, 0.5 part of aminophylline, 0.1 part of anthocyanidin, 8 parts of morroniside, maleic acid chlorobenzene 18 parts of that quick 0.1 part, 0.5 part of oryzanol, 2 parts of budesonide, 2 parts of amino acid and ethanol solution.General flavone is using flavonols, double The mixture of flavones and chalcone, tartaric acid uses malic acid, and amino acid is using glutamic acid and the mixture of lysine.
The preparation method of the medicine of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, chlorphenamine maleate and budesonide are crushed and 100 mesh sieves are crossed Son, obtains metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder and budesonide powder, standby With；
Step 2, by malic acid, general flavone, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder End and budesonide powder are added in ethanol solution and mixer is stirred 15 minutes with the rotating speed of 60rpm at normal temperatures, obtains First mixed solution；
Step 3, by mannitol, chlorpheniramine, anthocyanidin and oryzanol add the first mixed solution in and stir, while stirring Amino acid is added, is added completely into after amino acid finishes, mixer is stirred 60 minutes under 35 degrees Celsius with the rotating speed of 240rpm, then Relative density is 1.22 when carrying out being concentrated under reduced pressure into 65 DEG C, obtains concentrate, then be spray-dried obtaining dry extract, is added Plus auxiliary material is made pulvis, capsule, tablet or granule.
Embodiment 2
A kind of medicine for treating bronchitis, is made up of following raw material according to weight portion：6 parts of auxiliary material, 1.5 parts of tartaric acid, general flavone 5 Part, 2 parts of mannitol, 7 parts of chlorpheniramine, 6 parts of metronidazole, 1.5 parts of aminophylline, 0.7 part of anthocyanidin, 11 parts of morroniside, maleic acid chlorine 22 parts of that quick 0.3 part of benzene, 1 part of oryzanol, 3.5 parts of budesonide, 4 parts of amino acid and ethanol solution.Auxiliary material uses dextrin, lactose With the mixture of starch, the weight fraction of ethanol solution is 54%.
The preparation method of the medicine of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, chlorphenamine maleate and budesonide are crushed and 110 mesh sieves are crossed Son, obtains metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder and budesonide powder, standby With；
Step 2, by tartaric acid, general flavone, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder Added in ethanol solution with budesonide powder and mixer is stirred 20 minutes with the rotating speed of 90rpm at normal temperatures, obtain the One mixed solution；
Step 3, by mannitol, chlorpheniramine, anthocyanidin and oryzanol add the first mixed solution in and stir, while stirring Amino acid is added, is added completely into after amino acid finishes, mixer is stirred 60 minutes under 39 degrees Celsius with the rotating speed of 210rpm, then Relative density is 1.24 when carrying out being concentrated under reduced pressure into 65 DEG C, obtains concentrate, then be spray-dried obtaining dry extract, is added Plus auxiliary material is made pulvis, capsule, tablet or granule.
Embodiment 3
A kind of medicine for treating bronchitis, is made up of following raw material according to weight portion：7 parts of auxiliary material, 3.5 parts of tartaric acid, general flavone 6.5 parts, 3 parts of mannitol, 9 parts of chlorpheniramine, 11 parts of metronidazole, 2.5 parts of aminophylline, 1.2 parts of anthocyanidin, 13 parts of morroniside, Malaysia 28 parts of 0.4 part of sour chlorphenamine, 1.6 parts of oryzanol, 5.4 parts of budesonide, 5 parts of amino acid and ethanol solution.General flavone is used Flavanols, tartaric acid uses serine using sugarcane acid and the mixture of tussol, amino acid.Auxiliary material using carboxymethylcellulose calcium and The mixture of stevioside, the weight fraction of ethanol solution is 60%.
The preparation method of the medicine of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, chlorphenamine maleate and budesonide are crushed and 120 mesh sieves are crossed Son, obtains metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder and budesonide powder, standby With；
Step 2, by tartaric acid, flavanols, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder Added in ethanol solution with budesonide powder and mixer is stirred 24 minutes with the rotating speed of 100rpm at normal temperatures, obtain the One mixed solution；
Step 3, by mannitol, chlorpheniramine, anthocyanidin and oryzanol add the first mixed solution in and stir, while stirring Serine is added, is added completely into after amino acid finishes, mixer is stirred 75 minutes under 42 degrees Celsius with the rotating speed of 300rpm, then Relative density is 1.28 when carrying out being concentrated under reduced pressure into 65 DEG C, obtains concentrate, then be spray-dried obtaining dry extract, is added Plus auxiliary material is made pulvis, capsule, tablet or granule.
Embodiment 4
A kind of medicine for treating bronchitis, is made up of following raw material according to weight portion：8 parts of auxiliary material, 4 parts of tartaric acid, general flavone 8 Part, 4 parts of mannitol, 10 parts of chlorpheniramine, 12 parts of metronidazole, 3 parts of aminophylline, 1.5 parts of anthocyanidin, 15 parts of morroniside, maleic acid chlorine 32 parts of that quick 0.5 part of benzene, 2 parts of oryzanol, 6 parts of budesonide, 6 parts of amino acid and ethanol solution.General flavone is using flavonols, double The mixture of flavones, isoflavones, flavanols and chalcone, tartaric acid is using malic acid, citric acid, sugarcane acid and the mixing of tussol Thing, amino acid uses the mixture of glutamic acid, lysine, aspartic acid and serine.Auxiliary material uses dextrin, lactose, starch, first The mixture of base cellulose, carboxymethylcellulose calcium and stevioside, the weight fraction of ethanol solution is 65%.
The preparation method of the medicine of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, chlorphenamine maleate and budesonide are crushed and 110 mesh sieves are crossed Son, obtains metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder and budesonide powder, standby With；
Step 2, by tartaric acid, general flavone, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder Added in ethanol solution with budesonide powder and mixer is stirred 20 minutes with the rotating speed of 120rpm at normal temperatures, obtain the One mixed solution；
Step 3, by mannitol, chlorpheniramine, anthocyanidin and oryzanol add the first mixed solution in and stir, while stirring Amino acid is added, is added completely into after amino acid finishes, mixer is stirred 60 minutes under 48 degrees Celsius with the rotating speed of 360rpm, then Relative density is 1.25 when carrying out being concentrated under reduced pressure into 65 DEG C, obtains concentrate, then be spray-dried obtaining dry extract, is added Plus auxiliary material is made pulvis, capsule, tablet or granule.
500 patients of selection, men and women respectively accounts for half.500 patient's stochastic averaginas are divided into 5 groups and every group in sex and It is almost identical on age.Patient by the product of embodiment 1-4 to 1-4 groups takes, and existing product is taken to 5 groups of patients, often It three times, each 4g and warm water delivery service is used, continue two weeks, therapeutic effect is shown in Table 1.Treatment standard：Cure：Thoroughly eradicate Chronic bronchitis, clinical symptom disappearance no longer recurs in two years；Effectively：Clinical symptoms are obviously improved；It is invalid：Clinical symptoms Substantially do not change, or even aggravate.
Table 1
Cure quantity（People） Effective quantity（People） Invalid quantity（People） Cure rate（%） It is efficient（%）
1 group 78 21 1 78 99
2 groups 83 15 2 83 98
3 groups 86 13 1 86 99
4 groups 75 25 0 75 100
5 groups 47 26 27 47 73
As it can be seen from table 1 the cure rate of the product of embodiment 1-4 is more than 75%, significantly larger than the 47% of existing product；Implement More than 98%, significantly larger than the 73% of existing product, the product of embodiment 1-4 is used the effective percentage of the product of example 1-4 in patient During, there is not any discomfort in patient.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined May be appreciated other embodiment.

Claims (4)

1. a kind of medicine for treating bronchitis, it is characterised in that be made up of according to weight portion following raw material：Auxiliary material 4-8 parts, fruit Sour 0.5-4 parts, general flavone 3-8 parts, mannitol 1-4 parts, chlorpheniramine 5-10 parts, metronidazole 4-12 parts, aminophylline 0.5-3 parts, flower Blue or green 0.1-1.5 parts of element, morroniside 8-15 parts, chlorphenamine maleate 0.1-0.5 parts, oryzanol 0.5-2 parts, budesonide 2-6 Part, amino acid 2-6 parts and ethanol solution 18-32 parts.
2. it is according to claim 1 treatment bronchitis medicine, it is characterised in that the general flavone using flavonols, One or more mixture of biflavone, isoflavones, flavanols and chalcone, tartaric acid uses malic acid, citric acid, sugarcane Acid and one or more mixture of tussol, amino acid is using the one of glutamic acid, lysine, aspartic acid and serine Plant or various mixtures.
3. it is according to claim 1 and 2 treatment bronchitis medicine, it is characterised in that the auxiliary material use dextrin, breast The mixture of one or more of sugar, starch, methylcellulose, carboxymethylcellulose calcium and stevioside, the weight point of ethanol solution Number is 45-65%.
4. the preparation method of the medicine of a kind for the treatment of bronchitis as described in claim 1-3 is any, it is characterised in that specific Step is as follows：
Step one, metronidazole, aminophylline, morroniside, chlorphenamine maleate and budesonide are crushed and 100-120 mesh is crossed Sieve, obtains metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder and budesonide powder, standby With；
Step 2, by tartaric acid, general flavone, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate powder Added in ethanol solution with budesonide powder and mixer stirred 15-30 minutes with the rotating speed of 60-120rpm at normal temperatures, Obtain the first mixed solution；
Step 3, by mannitol, chlorpheniramine, anthocyanidin and oryzanol add the first mixed solution in and stir, while stirring Amino acid is added, is added completely into after amino acid finishes, mixer is stirred under 35-48 degrees Celsius with the rotating speed of 150-360rpm 45-90 minutes, then relative density is 1.20-1.30 when carrying out being concentrated under reduced pressure into 65 DEG C, obtains concentrate, then to carry out spraying dry Dry to obtain dry extract, addition auxiliary material is made pulvis, capsule, tablet or granule.
CN201611115454.9A 2016-12-07 2016-12-07 It is a kind of to treat medicine of bronchitis and preparation method thereof Withdrawn CN106727641A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611115454.9A CN106727641A (en) 2016-12-07 2016-12-07 It is a kind of to treat medicine of bronchitis and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611115454.9A CN106727641A (en) 2016-12-07 2016-12-07 It is a kind of to treat medicine of bronchitis and preparation method thereof

Publications (1)

Publication Number Publication Date
CN106727641A true CN106727641A (en) 2017-05-31

Family

ID=58876997

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611115454.9A Withdrawn CN106727641A (en) 2016-12-07 2016-12-07 It is a kind of to treat medicine of bronchitis and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106727641A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1762493A (en) * 2004-10-19 2006-04-26 上海中西制药有限公司 Process for preparing compound aminophylline tablet
CN103989695A (en) * 2014-06-06 2014-08-20 杨献华 Pharmaceutical composition for treating bronchial asthma and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1762493A (en) * 2004-10-19 2006-04-26 上海中西制药有限公司 Process for preparing compound aminophylline tablet
CN103989695A (en) * 2014-06-06 2014-08-20 杨献华 Pharmaceutical composition for treating bronchial asthma and application thereof

Similar Documents

Publication Publication Date Title
CN104274857A (en) Bactericidal traditional Chinese medicinal incense capable of purifying air and preparation method thereof
CN106723075A (en) A kind of double ginseng sea-buckthorn G-protein saline cistanche zinc selenium preparations and preparation method thereof
CN106727641A (en) It is a kind of to treat medicine of bronchitis and preparation method thereof
CN104026676A (en) Plantain herb soup with function of clearing away heat and toxic materials and production method thereof
CN104435216A (en) Ephedra and apricot cough relieving traditional Chinese medicine dispersible tablet and preparation method thereof
CN103704514B (en) Feed being used for the treatment of porcine contagious pleuropneumonia and preparation method thereof
CN106692170A (en) Medicine for treating bronchitis and preparing method thereof
CN110201054A (en) A kind of preparation method of anaesthetic composition and its pill that treating thyroid disease
CN106511363A (en) Western medicine composition for treating bronchitis and preparation method of western medicine composition
CN102499970B (en) Pure Chinese medicinal composition for treating bovine grainsick and preparation method thereof
CN101130016A (en) Erpi digestive pill
CN101181448A (en) Oral administration proprietary Chinese medicine for curing facial palsy
CN107669899A (en) A kind of Chinese patent drug for treating chronic gastritis and preparation method thereof
CN104274856A (en) Incense for improving haze air and preparation method thereof
CN107648569A (en) A kind of relieving cough and reducing sputum tablet of Chinese medicine and preparation method thereof
CN106615660A (en) Premix feed capable of preventing and curing porcine reproductive and respiratory syndrome (PRRS) of pregnant sows, and preparation method of premix feed
CN105770002A (en) Nose spraying water and preparing method thereof
CN107260833B (en) A Chinese medicinal composition for treating acne, and preparation method thereof
CN105106296A (en) Traditional Chinese medicine styptic powder for treating haemorrhoid hemorrhage syndrome
CN104225548A (en) Formula and preparing method for infantile malnutrition external patch
CN107468934A (en) A kind of capsule medicine for treating chronic bronchitis and preparation method thereof
CN103933136A (en) Traditional Chinese medicinal preparation for treating hemorrhoid diseases and preparation method thereof
CN107789463A (en) A kind of Chinese patent drug for treating chronic enteritis and preparation method thereof
CN101721671B (en) Externally applied traditional Chinese medicine composition for treating pulmonary emphysema
CN102397383B (en) Compound propolis pure Chinese medicinal composition for treating avian spirochaetosis and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170531

WW01 Invention patent application withdrawn after publication